For the quarter ending 2025-03-31.
| Income Statement | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Restructuring | 133 | 1,266* | 878 | 54 |
| Impairment | - | 3,488* | 172 | - |
| Research and development | 12,859 | 15,795* | 15,565 | 19,749 |
| General and administrative | 6,886 | 4,211* | 6,732 | 3,945 |
| Total operating expenses | 19,878 | 24,759* | 23,347 | 23,748 |
| Revenue from collaboration and licensing | 2,004 | 35,037* | 4,703 | 1,290 |
| (gain) income from operations | -17,874 | 10,278* | -18,644 | -22,458 |
| Other income (expense), net | 1,984 | -5,640* | 1,811 | -218 |
| Interest expense | - | 1* | - | - |
| Interest income | 236 | 878* | 809 | 1,073 |
| Grant income | 227 | 360* | 2,183 | 2,508 |
| Total other income, net | 2,447 | -4,403* | 4,803 | 3,363 |
| Net (gain) income before tax | -15,427 | 5,875* | -13,841 | -19,095 |
| Income tax expense | - | -26* | - | - |
| Net (gain) income | -15,427 | 5,901* | -13,841 | -19,095 |
| Foreign currency translation (loss) gain, net of tax | -1,354 | 4,619* | -1,360 | 178 |
| Comprehensive (gain) income | -16,781 | 10,520 | -15,201 | -18,917 |
| Basic EPS | -1.23 | 0.839 | -1.1 | -1.52 |
| Diluted EPS | -1.23 | 0.839 | -1.1 | -1.52 |
| Basic Average Shares | 12,544,777 | 12,538,834 | 12,538,774 | 12,538,774 |
| Diluted Average Shares | 12,544,777 | 12,538,834 | 12,538,774 | 12,538,774 |
HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Inc. (HOOK)